Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Merck & Co (NY:MRK)

146.31 -2.97 (-1.99%)
Streaming Delayed Price Updated: 12:28 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,015,614
Open 148.94
Bid (Size) 146.28 (100)
Ask (Size) 146.35 (100)
Prev. Close 149.28
Today's Range 146.22 - 149.27
52wk Range 78.03 - 156.92
Shares Outstanding 2,531,374,696
Dividend Yield 2.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Healthcare Dividend Stocks Offering More Than Just Income ↗
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027. 
Via MarketBeat
News headline image
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+37.4%
+37.4%
1 Month
-1.0%
-1.0%
3 Month
+13.9%
+13.9%
6 Month
+21.6%
+21.6%
1 Year
+86.2%
+86.2%

More News

Read More
News headline image
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
3 Cash-Producing Stocks with Open Questions
Via StockStory
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
From Merck & Co., Inc.
Via Business Wire
Friday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Thursday. ↗
Via Chartmill
Thursday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
From Merck & Co.
Via Business Wire
Wednesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
3 Healthcare Stocks with Warning Signs
Via StockStory
Tuesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
From Merck & Co., Inc.
Via Business Wire
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Via The Motley Fool
News headline image
3 Reasons to Sell MRK and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
These dow jones stocks are moving in today's session ↗
Via Chartmill
Discover which dow jones stocks are making waves on Monday. ↗
Via Chartmill
News headline image
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 146.31
When was Merck & Co last traded?
The last trade of Merck & Co was at 09/30/26 12:28 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 370.38B
How many shares of Merck & Co are outstanding?
Merck & Co has 370B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.